Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
sodium-potassium pump inhibitor
Digoxin is a sodium-potassium pump inhibitor.- Ella Martin, .et al. , ACS Pharmacol Transl Sci, 2025, May 12;8(9):2996-3006 PMID: 40969890
- Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
-
Sodium Channel inhibitor
AmbroxolHCl is a potent inhibitor of the neuronal Na+ channels, inhibits TTX-resistant Na+ currents with IC50 of 35.2 uM and 22.5 μM for tonic and phasic block, inhibits TTX-sensitive Na+ currents with IC50 of 100 μM. Phase 3.- Giovanni Bocci, .et al. , ACS Pharmacol Transl Sci, 2020, Oct 14 PMID: 33330842
-
HIF-1α inhibitor
Minocycline hydrochloride is a broad-spectrum tetracycline antibiotic, acting by binding to the bacterial 30S ribosomal subunit and inhibiting protein synthesis.- Viktoria Lazar, .et al. , Nature, 2022, 610: 540-546 PMID: 36198788
-
PDE1 inhibitor
Vinpocetine is a Ca2+-calmodulin-dependent phosphodiesterase I (PDE1) inhibitor. -
Nav inhibitor
Nav1.7-IN-2 is an inhibitor of voltage-gated sodium channels (Nav), in particular Nav 1.7, with IC50 of 80 nM. -
SChE inhibitor
Dibucaine (USAN) is an amide local anesthetic. Dibucaine reversibly binds to and inactivates sodium channels in the neuronal cell membrane. Inhibition of sodium channels prevents the depolarization of nerve cell membranes and inhibits subsequent propagation of impulses along the course of the nerve, thereby limiting the excitation of nerve endings. This results in loss of sensation. -
sodium channel inhibitor
Levobupivacaine is a local anaesthetic drug belonging to the amino amide group. -
Nav1.7 Inhibitor
PF-05089771 is a Selective Nav1.7 Inhibitor (IC50 = 11 nM) that interacts with the voltage-sensor domain (VSD) of domain IV. -
Nav1.7 inhibitor
PF-05241328 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channels (Nav1.7), with an IC50 of 31 nM. -
SLC13A5 inhibitor
BI01383298 is a potent inhibitor of SLC13A5, being selective over other family members and other transporters. -
Na+/H+ exchanger inhibitor
5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) derives from an amiloride and is a potent Na+/H+ exchanger inhibitor, which decreases the intracellular pH (pHi) and induces apoptosis in leukemic cells. -
NaV 1.7 inhibitor
NaV1.7 inhibitor-1 is an efficacious voltage-gated sodium channel (NaV) 1.7 inhibitor with an IC50 of 0.6 nM for hNaV1.7, exhibits 80-fold selectivity versus hNaV1.5. -
SLC34A1 inhibitor
PF-06869206 is an orally bioavailable selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1) with an IC50 of 380 nM. -
Sodium Channel inhibitor
Sodium Channel inhibitor 1, one of 3-Oxoisoindoline-1-carboxamides, is a novel and selective voltage-gated sodium channel for pain treatment. -
voltage-gated sodium channel Nav1.7 inhibitor
Nav1.7-IN-3 is a selective, orally bioavailable voltage-gated sodium channel Nav1.7 inhibitor with an IC50 of 8 nM. Pain relief. Limited CNS penetration. -
NaV1.3 and NaV1.1 channels inhibitor
ICA-121431 is a potent and selective inhibitor of human NaV1.3 and NaV1.1 channels (IC50 values are 13 and 23 nM respectively). -
sodium channel protein inhibitor
Oxcarbazepine is a sodium channel protein inhibitor. -
SGLT2 inhibitor
PF-04971729 is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2. -
Sodium channel blocker/DNMT inhibitor
Procainamide HCl is a sodium channel blocker, and also a DNA methyltransferase inhibitor. -
Sodium Channel Inhibitor
Articaine is a selective inhibitor of voltage-gated sodium channels, including rNav1.4, hNav1.7, and rNav1.8, demonstrating an IC50 of 15.8 μM for open-state Na+ channels. It effectively blocks Na+ influx, leading to local anesthetic effects and interruption of nerve impulse conduction. Additionally, Articaine exhibits anti-inflammatory properties by inhibiting NF-κB activation and the NLRP3 inflammasome pathway. This compound is valuable for research in dental anesthesia and inflammatory-related conditions, such as acute kidney injury. -
glutamate release inhibitor
Sipatrigine, a neuroprotective agent, is a glutamate release inhibitor, voltage-dependent sodium channel and calcium channel inhibitor, penetrating the central nervous system. Has potential to treat focal cerebral ischemia and stroke. -
Nav1.7 sodium channel inhibitor
Raxatrigine hydrochloride (GSK-1014802 hydrochloride) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor. -
inhibitor of Kv2.1 and Kv2.2
RY785 (Kv2-IN-A1) is an inhibitor of Kv2.1 and Kv2.2. -
Sodium Channel Inhibitor
Lamotrigine-13C3 is a stable isotope-labeled derivative of Lamotrigine, a highly effective sodium channel inhibitor. This compound selectively targets voltage-gated Na+ channels, leading to stabilization of presynaptic neuronal membranes and a subsequent reduction in glutamate release. Lamotrigine-13C3 is suitable for research applications related to epilepsy, focal seizures, and other neurological disorders. -
Furin Inhibitor
BOS-318 is a highly selective and cell-permeable inhibitor of furin, exhibiting an IC50 value of 1.9 nM. This compound demonstrates the ability to protect epithelial sodium channels (ENaC) from activation by neutrophil elastase. BOS-318 is a valuable tool for research focused on cystic fibrosis and related pulmonary conditions. -
Sodium Channel Inhibitor
Mepivacaine hydrochloride is a sodium channel inhibitor that selectively binds to voltage-gated sodium ion channels in neuronal cell membranes. By inhibiting sodium influx and membrane depolarization, it provides significant local anesthetic effects. This compound is widely used in research applications related to nerve conduction studies and pain management investigations. -
Bacterial Inhibitor
Methyl Paraben is a bacterial inhibitor primarily used as a preservative in various applications due to its stability and non-volatility. It has been shown to enhance histamine release and modulate cellular immune responses, in addition to blocking sodium channels. Its properties make it valuable for studies exploring microbial inhibition and the mechanisms of ischemia-reperfusion injury. -
Dopamine Receptor Inhibitor
Fluphenazine dihydrochloride is a potent dopamine receptor antagonist primarily targeting dopamine D2 receptors in the mesolimbic, nigrostriatal, and tuberoinfundibular pathways. This phenothiazine derivative also exhibits the ability to inhibit neuronal voltage-gated sodium channels. Its key biological activities include the suppression of Methylphenidate-induced stereotyped behaviors and climbing in murine models. Fluphenazine dihydrochloride is widely utilized in research related to psychosis, diabetic peripheral neuropathy, and may also have implications for the inhibition of SARS-CoV-2. -
Sodium Channel Inhibitor
Oxybuprocaine hydrochloride is a sodium channel inhibitor that reversibly blocks sodium channels, effectively preventing the propagation of painful nerve impulses in tissues such as the cornea, conjunctiva, and sclera. This compound is primarily utilized in ophthalmology and otolaryngology for its anesthetic properties, providing localized pain relief during various medical procedures. Its ability to inhibit nerve signal transmission makes it valuable for both diagnostic and therapeutic applications in ocular and ear, nose, and throat treatments. -
Sodium Channel Inhibitor
Propafenone hydrochloride is a sodium channel inhibitor primarily used as an anti-arrhythmic agent. It effectively treats conditions related to rapid heartbeats, including atrial and ventricular arrhythmias. This compound is useful in research applications focused on cardiac rhythm disturbances and the pharmacological modulation of ion channels. -
Sodium Channel Inhibitor
Triamterene is a sodium channel inhibitor that selectively blocks epithelial Na+ channels (ENaC) in a voltage-dependent manner. It exhibits mild diuretic properties and is utilized in the management of conditions related to fluid retention. Additionally, Triamterene serves as an inhibitor of the TGR5 receptor, contributing to its diverse biological effects and applications in research related to renal and metabolic processes. -
Sodium Channel Inhibitor
Ropivacaine mesylate acts primarily as a sodium channel inhibitor, serving as a long-acting amide local anesthetic. It effectively blocks impulse conduction by reversibly inhibiting sodium ion influx in nerve fibers, making it suitable for procedures requiring spinal block anesthesia. Additionally, Ropivacaine has been identified as an inhibitor of the K2P potassium channel TREK-1, exhibiting an IC50 value of 402.7 μM in COS-7 cell membranes. This compound is relevant for research into pain management and neuronal activity modulation. -
Sodium Channel Inhibitor
Mepivacaine is an amide-type local anesthetic that functions as a sodium channel inhibitor. By binding to specific voltage-gated sodium ion channels in neuronal cell membranes, Mepivacaine effectively inhibits sodium influx and membrane depolarization. This agent is primarily utilized in various research applications within the fields of pain management and anesthesia. -
Sodium Channel Inhibitor
Riluzole hydrochloride is a sodium channel inhibitor that exhibits anticonvulsant properties. It functions primarily as a use-dependent Na+ channel blocker and also has the capability to inhibit GABA uptake, with an IC50 of 43 μM. This compound is commonly utilized in neurological research applications, particularly in studies focused on epilepsy and neuroprotection. -
Sodium Channel Inhibitor
Ropivacaine hydrochloride is a potent sodium channel inhibitor that effectively disrupts impulse conduction by reversibly blocking sodium ion influx in nerve fibers. Additionally, it inhibits the K2P TREK-1 potassium channel with an IC50 of 402.7 μM in COS-7 cell membranes. This compound is primarily applied in the management of neuropathic pain in various in vivo research contexts. -
Sodium Channel Inhibitor
Propoxycaine hydrochloride is a sodium channel inhibitor that disrupts voltage-gated sodium channel activity, leading to a reduction in ionic flux essential for the initiation and propagation of action potentials. This compound is primarily utilized in research to investigate sensory nerve function and analgesic mechanisms, resulting in local anesthetic effects characterized by a loss of sensation. -
Nav1.7 Inhibitor
Nav1.7-IN-22 is a selective inhibitor of the voltage-gated sodium channel Nav1.7. By blocking the activity of Nav1.7, this compound effectively inhibits abnormal electrical signal generation and conduction in sensory neurons. Nav1.7-IN-22 is utilized in research focused on pain mechanisms, providing insights into potential therapeutic applications for pain management. -
Sodium Channel Inhibitor
Decarbamoylsaxitoxin is a potent sodium channel inhibitor that selectively blocks the influx of sodium ions in excitable tissues, such as nerve and skeletal muscle cells, thus preventing action potential generation. As a hydrolysis product of saxitoxin, Decarbamoylsaxitoxin exhibits similar neurotoxic effects, including the ability to inhibit veratridine- and ouabain-induced neuroblastoma cell swelling and lysis. This reagent is valuable for research involving mechanisms of paralytic shellfish poisoning and sodium channel pharmacology. -
NET Inhibitor
Nisoxetine is a potent and selective inhibitor of the norepinephrine transporter (NET) with a Kd of 0.76 nM. This compound exhibits antidepressant properties and functions as a local anesthetic, in addition to blocking voltage-gated sodium channels. Its mechanisms make it valuable for research in neuropharmacology and the investigation of depression and pain pathways.
